Numerous studies have demonstrated that KDM6A is targeted by loss-of-function mutations as a suppressor in various cancers, including acute myeloid leukemia, B cell lymphoma, multiple myeloma, non-small cell lung cancer, squamous-like pancreatic cancer, T-cell acute lymphoblastic leukemia, urothelial cancer, colorectal cancer, medulloblastoma, breast cancer, hepatocellular cancer and esophageal squamous cell cancer (50–58, 60, 61, 67–73, 118). The gene discussed is KDM6A; the disease is plasma cell myeloma.